Colic Clinical Trial
Official title:
Efficacy and Tolerability of a Composition Comprising of HMO in a Supplement Format on Colic Management: a Double-blind, Randomized, Placebo-controlled Trial
Efficacy and tolerability of a composition comprising of HMO in a supplement format on colic management: a double-blind, randomized, placebo-controlled trial
Status | Recruiting |
Enrollment | 144 |
Est. completion date | December 31, 2024 |
Est. primary completion date | September 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Weeks to 12 Weeks |
Eligibility | Inclusion criteria: 1. Infants 2 weeks - 12 weeks of age at enrolment 2. Infants diagnosed with colic according to Rome IV criteria: Diagnostic criteria for research purposes (infant must meet all Rome IV criteria): 1. An infant who is less than 5 months of age (in the current clinical trial, only infants 2 weeks to 8 weeks of age will be enrolled) when the symptoms start and stop 2. Recurrent and prolonged periods of infant crying, fussing, or irritability reported by caregivers that occur without obvious cause and cannot be prevented or resolved by caregivers 3. No evidence of infant failure to thrive, fever, or illness 4. Excessive crying/fussiness for 3 or more hours per day during 3 or more days in the past 7 days as reported by parents to the clinician 5. Total 24-hour crying plus fussing is 3 hours or more when measured by at least one prospectively kept 24-hour behavior diary. (The Structured Infant Crying and Fussing Diary will be dispensed at the screening visit (V0), completed for two 24-hour periods at H0 (days -3 to -1), and returned at V1 to be used as part of the diagnostic criteria for infantile colic.) 3. Term infants (= 37 weeks) generally healthy with normal birth weight (=2.5kg) and singleton born 4. Predominantly formula fed* (formula fed = 80% of the time) for at least 7 days before randomization and the choice of formula feeding has been made by the parents before the beginning of the trial. 5. Infants who have been on the same formula for the past 5 days 6. Signed informed consent obtained for infant's and parents'/Legally Acceptable Representative (LAR) participation in the study 7. Parent/LAR of infant agrees not to enroll infant in another interventional clinical research study while participating in this study 8. Parent of the infant/LAR is willing and able to fulfill the requirements of the study protocol 9. Parent of infant can be contacted throughout the study - Predominantly formula feeding defined in the study means that the infant's predominant source of nourishment is formula. Specifically, infants are fed with formula for at least 80% of total milk feeds per day. Exclusion criteria: 1. Presence of any congenital condition and/or previous or current illness/infection and (or) medication use that could interfere with the main study outcomes. 2. Clinical evidence of chronic illness or gastrointestinal disorders, major medical problems (e.g. ill, immunocompromised, major developmental or genetic abnormality). 3. Known cow's milk protein allergy, lactose intolerance, or galactosaemia; including presence of any allergic manifestations. 4. Received any special formula (e.g. lactose-free, hydrolyzed protein) within 5 days before randomization or switched formulas within 5 days before randomization. 5. Received any of the following products/medication within 5 days before randomization: - Antibiotics - Alginate - Prokinetics - Proton pump inhibitors - Simethicone - L. reuteri probiotic - Formula containing Human milk Oligosaccharides 6. Other infant(s) <6months of age living in the same household. 7. Current participation in another interventional clinical trial. |
Country | Name | City | State |
---|---|---|---|
Italy | Ospedale Pediatrico Giovanni XXIII, Policlinico di Bari | Bari | |
Italy | ASST FBF Sacco | Milano | |
Italy | AOUP Paolo Giaccone | Palermo | |
Italy | Azienda Ospedaliero -Universitaria Pisana | Pisa | |
Spain | Centro de Salud El Ranero | Murcia | |
Spain | Hospital Clínico Universitario de Santiago de Compostela | Santiago de Compostela | |
Spain | Unidad de Estudios e Investigación IHP | Sevilla |
Lead Sponsor | Collaborator |
---|---|
Société des Produits Nestlé (SPN) |
Italy, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Duration and number of episodes of infant crying type based on a crying-type classification of the audio recording | Duration and number of episodes of each infant crying type (pain, fussiness, hunger) based on a crying-type classification of the audio recording | 24 hours after V1 (day 0), V2 (day 7), V3 (day 14) and for 3 days prior to V4 (day 21) | |
Other | Proportion of children with a specific crying type based on a crying-type classification of the audio recording | Proportion of children with a specific crying type (pain, fussiness, hunger) based on a crying-type classification of the audio recording | 24 hours after V1 (day 0), V2 (day 7), V3 (day 14) and for 3 days prior to V4 (day 21) | |
Other | Duration of crying based on a crying-type classification of the audio recording | Duration of crying based on a crying-type classification of the audio recording | 24 hours after V1 (day 0), V2 (day 7), V3 (day 14) and for 3 days prior to V4 (day 21) | |
Other | Duration of fussing based on a crying-type classification of the audio recording | Duration of fussing based on a crying-type classification of the audio recording | 24 hours after V1 (day 0), V2 (day 7), V3 (day 14) and for 3 days prior to V4 (day 21) | |
Other | Duration of crying and fussing combined based on a crying-type classification of the audio recording | Duration of crying and fussing combined based on a crying-type classification of the audio recording | 24 hours after V1 (day 0), V2 (day 7), V3 (day 14) and for 3 days prior to V4 (day 21) | |
Other | Crying and fussing comparison between the structured infant crying and fussing diary and the crying-type classification of the recording of infant crying/fussing across the intervention | Infant daily crying and fussing duration compared between the structured infant crying and fussing diary and the crying-type classification of the recording of infant crying/fussing across the intervention | V1 (day 0), V2 (day 7), V3 (day 14) and V4 (day 21) | |
Other | Maternal Postpartum depression/ anxiety | Maternal postpartum depressive and anxiety symptoms assessed using an Edinburgh postnatal depression scale (EPDS) | V1 (day 0) and V4 (day 21) | |
Primary | Difference in average infant daily crying and fussing duration | Difference in average infant daily crying and fussing duration at the end of the intervention in the Intervention Group (IG) versus the Control Group (CG). The crying and fussing duration is measured using a structured infant crying and fussing diary. | At the end of the intervention period (day 21) | |
Secondary | Modulation of infant gut microbiota (communities of microbes, their taxonomy, strain composition, diversity, ecology, functionalities, and the metabolites produced) | Modulation of infant gut microbiota in the intervention group versus the control group assessed using metagenomics | V1 (day 0), V2 (day 7), and V4 (day 21) | |
Secondary | Difference in average infant daily crying duration | Difference in average infant daily crying duration at the end of the intervention in the IG versus the CG assessed using a structured infant crying and fussing diary. | Change from baseline (V1) to intervention end (V4) | |
Secondary | Difference in average infant daily fussing duration | Difference in average infant daily fussing duration at the end of the intervention in the IG versus the CG assessed using a structured infant crying and fussing diary. | Change from baseline (V1) to intervention end (V4) | |
Secondary | Difference in average infant daily crying and fussing duration in the IG | Difference in average infant daily crying duration and fussing duration combined from baseline (V1) to intervention end (V4) in the IG assessed using a structured infant crying and fussing diary. | Change from baseline (V1) to intervention end (V4) | |
Secondary | Difference in average infant daily crying duration in the Intervention group | Difference in average infant daily crying duration from baseline (V1) to intervention end (V4) in the Intervention group assessed using a structured infant crying and fussing diary. | Change from baseline (V1) to intervention end (V4) | |
Secondary | Difference in average infant daily fussing duration in the Intervention group | Difference in average infant daily fussing duration from baseline (V1) to intervention end (V4) in the interventional group assessed using a structured infant crying and fussing diary. | Change from baseline (V1) to intervention end (V4) | |
Secondary | Infant daily crying and fussing duration assessed longitudinally | Infant daily crying and fussing duration combined assessed longitudinally across the intervention assessed using a structured infant crying and fussing diary. | Longitudinal changes across specific visits V1 (day 0), V2 (day 7), V3 (day 14) and V4 (day 21) | |
Secondary | Infant crying/fussing per 24 hours | Episodes of infant crying/fussing per 24 hours assessed using a structured infant crying and fussing diary. | At specific visits V1 (day 0), V2 (day 7), V3 (day 14) and V4 (day 21) | |
Secondary | Percentage of children achieving a reduction in daily crying and fussing | Percentage of children achieving a reduction in daily crying, fussing, crying and fussing time combined of = 25 % and = 50 % assessed using a structured infant crying and fussing diary. | At specific visits V1 (day 0), V2 (day 7), V3 (day 14) and V4 (day 21) | |
Secondary | Incidence of infantile colic | Incidence of infantile colic assessed using a structured infant crying and fussing diary. | At specific visits V1 (day 0), V2 (day 7), V3 (day 14) and V4 (day 21) | |
Secondary | Parental perception of colic severity | Parental perception of colic severity assessed using a 10-cm visual analog scale (VAS) | At specific visits V1 (day 0), V2 (day 7), V3 (day 14) and V4 (day 21) | |
Secondary | Overall GI tolerance and individual GI symptoms | Overall infant GI tolerance and individual GI and GI-related symptoms (stooling, spitup/ vomiting, gassiness, crying, fussiness) assessed using IGSQ-13 | V1 (day 0), V2 (day 7), V3 (day 14) and V4 (day 21) | |
Secondary | Overall GI tolerance and individual GI symptoms | Change in IGSQ-13 scores assessed using IGSQ-13 | Baseline to intervention end (day 21) | |
Secondary | Overall GI tolerance and individual GI symptoms | Functional GI symptoms (regurgitation, consistency of stools), crying, allergic symptoms (atopic eczema) and respiratory symptoms assessed using CoMiSS | At V1 (day 0), V2 (day 7), V3 (day 14) and V4 (day 21) | |
Secondary | Overall GI tolerance and individual GI symptoms | Change in CoMiSS scores assessed using CoMiSS | From baseline to intervention end (day 21) | |
Secondary | Overall GI tolerance and individual GI symptoms | Stool consistency, spitting up/vomiting and flatulence assessed using 1-day retrospective GI diary at V1 (day 0) and prospective 3-Day GI symptom diary diaries at home (H2, H3 and H4) just prior to V2 (day 7), V3 (day 14) and V4 (day 21) | 1-day retrospective GI diary at V1 (day 0) and prospective 3-Day GI symptom diary diaries at home (H2, H3 and H4) just prior to V2 (day 7), V3 (day 14) and V4 (day 21) | |
Secondary | Infant sleep | Infant sleep duration and nighttime wakings per 24 hours assessed using Brief infant sleep questionnaire (BISQ) | V1 (day 0), V2 (day 7), V3 (day 14) and V4 (day 21) | |
Secondary | Infant Quality of life | Infant quality of life assessed using an Infant Quality of Life instrument. The tool includes IQI includes questions on 7 health items such as sleeping, crying, feeding , skin, breathing, playfulness and Interaction, and stooling. Each item consists of 4 levels, most of which are ranked by severity. | V1 (day 0), V2 (day 7), V3 (day 14) and V4 (day 21) | |
Secondary | Parental and family quality of life | Parental/family quality of life will be assessed using a Quality of Life Visual Analog Scale that rates the parent / family's quality of life based on a 10-point Likert scale. | V1 (day 0), V2 (day 7), V3 (day 14) and V4 (day 21) | |
Secondary | Infant fecal gut microbiota | Microbiome of fecal samples to investigate the communities of microbes, their taxonomy, strain composition, diversity, ecology, functionalities, and the metabolites produced assessed using metagenomics. | V1 (day 0), V2 (day 7), and V4 (day 21) | |
Secondary | Fecal metabolism | Fecal metabolism (pH, organic acids) | V1 (day 0), V2 (day 7), and V4 (day 21) | |
Secondary | Fecal markers of inflammation calprotectin | Inflammation biomarkers calprotectin assessed using ELISA. | V1 (day 0) and V4 (day 21) | |
Secondary | Fecal markers of inflammation lipocalin | Inflammation biomarkers lipocalin assessed using ELISA. | V1 (day 0) and V4 (day 21) | |
Secondary | Infant anthropometry weight | Weight in grams | V1 (day 0), V2 (day 7), V3 (day 14) (optional if V3 is a phone call) and V4 (day 21) | |
Secondary | Infant anthropometry length | Length in cm | V1 (day 0), V2 (day 7), V3 (day 14) (optional if V3 is a phone call) and V4 (day 21) | |
Secondary | Infant anthropometry head circumference | Head circumference in cm | V1 (day 0), V2 (day 7), V3 (day 14) (optional if V3 is a phone call) and V4 (day 21) | |
Secondary | Infant anthropometry weight gain | Weight gain in g/d | V1 (day 0), V2 (day 7), V3 (day 14) (optional if V3 is a phone call) and V4 (day 21) | |
Secondary | Infant anthropometry length gain | Length gain in cm/d | V1 (day 0), V2 (day 7), V3 (day 14) (optional if V3 is a phone call) and V4 (day 21) | |
Secondary | Infant illness and infection and medication usage | Data collected using a calendar-based electronic Infant Illness Diary (IID) | V1 (day 0) until V4 (day 21) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01849991 -
Safety and Effect of L. Reuteri on Biomarkers of Inflammation in Healthy Infants With Colic
|
Phase 1 | |
Completed |
NCT01279265 -
Effect of Lactobacillus Rhamnosus GG (LGG) on Infant Colic
|
N/A | |
Completed |
NCT00177086 -
Alfuzosin Hydrochloride to Promote Passage of Distal Ureteral Calculi
|
Phase 3 | |
Not yet recruiting |
NCT02577133 -
Prevention of Colic With the Probiotic Lactobacillus Reuteri
|
Phase 2/Phase 3 | |
Recruiting |
NCT01715220 -
Treatment of Suspected Cholelithiasis With Nitroglycerin
|
Phase 2 | |
Completed |
NCT00922727 -
Safety of Lactobacillus Reuteri (L. Reuteri) in Healthy Adults
|
Phase 1 | |
Completed |
NCT02865564 -
Effect of Lactobacillus Reuteri DSM17938 in Neonates Treated With Antibiotics
|
N/A | |
Completed |
NCT01997593 -
Peritoneal Ropivacaine Infiltration on Postoperative Pain in Children Affected
|
Phase 2 | |
Completed |
NCT01541046 -
Lactobacillus Reuteri DSM 17938 Versus Placebo in the Treatment of Infantile Colic
|
Phase 2 | |
Completed |
NCT00929292 -
Safety and Tolerance Study of Alpha-Lactalbumin Enriched and Probiotic-Supplemented Infant Formula in Infants With Colic
|
Phase 3 | |
Recruiting |
NCT01067027 -
Control of Colic in Infants by Dietary Supplementation With the Probiotic Lactobacillus Reuteri
|
Phase 4 | |
Recruiting |
NCT04983069 -
Neonatal Outcome of Children With Antenatal Colic Hyperechogenicity
|
||
Recruiting |
NCT05685030 -
Probiotics Strains for Infant Colic
|
Phase 2 | |
Withdrawn |
NCT05198700 -
The Effect of Probiotics on Symptoms of Infantile Colic
|
Phase 2 | |
Terminated |
NCT02586558 -
Effect of a Prebiotic on Colic and Crying and Fussing Behaviour in Infants
|
N/A | |
Completed |
NCT01532518 -
Preliminary Efficacy, Safety and Pharmacokinetics Study of Nepadutant in Infant With Feeding Intolerance
|
Phase 2 | |
Completed |
NCT00796523 -
An Intervention to Decrease Infant Crying
|
N/A | |
Completed |
NCT05052476 -
First Line Dose-efficacy Study of Bactecal® D Liquid for Infant Colic
|
N/A | |
Completed |
NCT02242292 -
Study to Evaluate Efficacy and Safety of Oral Doses of Hyoscine Butylbromide for the Treatment of Occasional Abdominal Pain, Cramping, and Discomfort
|
Phase 2 | |
Terminated |
NCT00139646 -
Parecoxib in Renal Colic
|
Phase 3 |